Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/12725
|
| Title: | Repurposing old drugs as antiviral agents for coronaviruses |
| Authors: | Yang, CW;Peng, TT;Hsu, HY;Lee, YZ;Wu, SH;Lin, WH;Ke, YY;Hsu, TA;Yeh, TK;Huang, WZ;Lin, JH;Sytwu, HK;Chen, CT;Lee, SJ |
| Contributors: | Institute of Biotechnology and Pharmaceutical Research;National Institute of Infectious Diseases and Vaccinology |
| Abstract: | BACKGROUND: New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2. METHODS: FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC(50)) of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined. The viabilities of Fcwf-4 and HCT-8 cells were measured by crystal violet staining and MTS/PMS assay, respectively. RESULTS: Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC(50) values ranging from 11 nM to 75 μM. They are all old drugs as follows, anisomycin, antimycin A, atovaquone, chloroquine, conivaptan, emetine, gemcitabine, homoharringtonine, niclosamide, nitazoxanide, oligomycin, salinomycin, tilorone, valinomycin, and vismodegib. CONCLUSION: All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effect on SARS-CoV-2, should be considered for immediate uses in COVID-19 patients. |
| Date: | 2020-08 |
| Relation: | Biomedical Journal. 2020 Aug;43(4):368-374. |
| Link to: | http://dx.doi.org/10.1016/j.bj.2020.05.003 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2319-4170&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000579445300011 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85086510043 |
| Appears in Collections: | [李秀珠] 期刊論文
[陳炯東] 期刊論文
[葉燈光] 期刊論文
[徐祖安] 期刊論文
[司徒惠康] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB32563698.pdf | | 1819Kb | Adobe PDF | 314 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
